Armin Wolf
A5075076772- Retinal Diseases and Treatments
- Retinal and Macular Surgery
- Glaucoma and retinal disorders
- Intraocular Surgery and Lenses
- Retinal and Optic Conditions
- Retinal Imaging and Analysis
- Kruppel-like factors research
- Fibroblast Growth Factor Research
- Corneal surgery and disorders
- Ocular Diseases and Behçet’s Syndrome
- Epigenetics and DNA Methylation
- Retinal Development and Disorders
- Historical, Literary, and Cultural Studies
- Corneal Surgery and Treatments
- Ocular Oncology and Treatments
- Ocular Surface and Contact Lens
- Vascular Malformations Diagnosis and Treatment
- Ocular Infections and Treatments
- Historical Legal Studies and Society
- Medieval European History and Architecture
- Historical Influence and Diplomacy
- Historical Geopolitical and Social Dynamics
- Retinopathy of Prematurity Studies
- Traumatic Ocular and Foreign Body Injuries
- Angiogenesis and VEGF in Cancer
University Hospital Ulm
2006-2025
Universität Ulm
1988-2025
Ophthalmology Clinic
2021-2025
Klinik und Poliklinik für Augenheilkunde Universitätsklinikum Regensburg
2021-2025
Ludwig-Maximilians-Universität München
2014-2024
LMU Klinikum
2004-2024
Knappschaftsklinikum Saar
2024
Augenklinik Heidelberg
2006-2023
Augenklinik Universitätsklinikum Würzburg
2020-2023
University Hospital of Basel
2023
In Brief Purpose: To evaluate the efficacy of bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) for treatment diabetic macular edema. Methods: This prospective, consecutive, noncomparative case series included 51 consecutive patients (26 females and 25 males; mean age, 64 years) with diffuse Inclusion criteria were determined independently size edema, retinal thickness, visual acuity, metabolic control, type diabetes, or previous treatments beyond a 6-month period. At each...
PurposeTo evaluate the efficacy of a single intravitreal injection rAAV2/2-ND4 in subjects with visual loss from Leber hereditary optic neuropathy (LHON).DesignRESCUE is multicenter, randomized, double-masked, sham-controlled, phase 3 clinical trial.ParticipantsSubjects m.11778G>A mitochondrial DNA mutation and vision ≤6 months onset 1 or both eyes were included.MethodsEach subject’s right eye was randomly assigned (1:1) to treatment (single 9 × 1010 viral genomes 90 μl) sham injection. The...
To investigate the possible protective effect of dietary antioxidant quercetin on retinal pigment epithelial (RPE) cell dysfunction and cellular senescence occurring in age-related macular degeneration (AMD). The major flavonoid was studied RPE cells vitro.Cultured human were incubated with different concentrations for 24 hours. Cells then treated 150 to 300 microM hydrogen peroxide 2 Mitochondrial function measured by using MTT assay vitality live-dead staining assay. Intracellular levels...
Background: This study examines the management and outcomes of large paranasal sinus osteomas (PSO), especially those abutting or encasing critical structures skull base orbit. Methodology: A multicentric retrospective analysis was conducted between June 2007 September 2023. The included surgically treated (regardless type approach chosen) PSO, exceeding 3 cm in diameter and/or located anatomical areas. An performed to assess association relationships, size, presence residual disease,...
To evaluate the effect of intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) injections on visual acuity and foveal retinal thickness in patients with central vein occlusion (CRVO).In this prospective, noncomparative, consecutive, interventional case series, 46 received repeated (1.25 mg) bevacizumab. Main outcome measures were (Snellen ETDRS charts) optical coherence tomography measurements a 6-month follow-up period.Mean improved from 20/250 at baseline to 20/80...
<h3>Purpose:</h3> To evaluate the effect of intravitreal bevacizumab (Avastin) injections on visual acuity (VA) and foveal retinal thickness in patients with macular oedema secondary to branch vein occlusion. <h3>Methods:</h3> A prospective, non-comparative, consecutive, interventional case series 34 patients. Patients received repeated 1.25 mg bevacizumab. Main outcome measures were VA (Snellen charts ETDRS) (optical coherence tomography measurements) a follow-up period 6 months....
To report on epiretinal membrane (ERM) characteristics and photoreceptor layer integrity of lamellar macular holes (LMHs) pseudoholes (MPHs), to compare with clinical course in operated untreated eyes.We consecutively reviewed the charts patients LMH MPH between 2003 2013. For analysis, we included 87 eyes (48 LMH, 39 MPH) a minimum follow-up 6 months. Of these, 64 (37 27 for high-resolution spectral domain optical coherence tomography analysis examinations fulfilling required resolution...
To assess healthcare processes during treatment of neovascular age-related macular degeneration (AMD) in patients under real-life conditions and evaluate efficacy monthly visual acuity (VA) assessment a pro re nata regime.A multicentre, prospective, non-interventional study based Germany included AMD treated with intravitreal ranibizumab. Patients completed 3-month loading phase injections 0.5 mg ranibizumab, followed by 12-month maintenance which investigators documented VA, additional...
To investigate preoperative ocular risk factors and indications for secondary intraocular lens (IOL) implantation compare postoperative complications, visual refractive outcomes in a tertiary referral center.Patients older than 14 years that underwent IOL had minimum follow-up of 3 months were enrolled this retrospective case series. Preoperative factors, surgery, including prediction error (PE) absolute (AE) evaluated. IOLs fixated following positions: anterior chamber (AC), retropupillary...
Abstract Genome-wide association studies (GWAS) for late stage age-related macular degeneration (AMD) have identified 52 independent genetic variants with genome-wide significance at 34 genomic loci. Typically, such an approach rarely results in the identification of functional implicating a defined gene disease process. We now performed transcriptome-wide study (TWAS) allowing prediction effects AMD-associated on expression. The TWAS was based genotypes 16,144 late-stage AMD cases and...
There is no evidence-based therapy for non-arteritic central retinal artery occlusion (NA-CRAO). Intravenous thrombolysis (IVT) with alteplase in a time window < 4.5 h may lead to favorable outcome. Purpose of this study was investigate the feasibility, efficacy and safety IVT patients classified as functionally blind.
Meta-analyses of case series non-arteritic central retinal artery occlusion (CRAO) indicate beneficial effects intravenous thrombolysis when initiated early after symptom onset. Randomized data are lacking to address this question.
Purpose.: In early exudative age-related macular degeneration (AMD), segmental thinning of Bruch's membrane is associated with ingrowth choroidal neovascularization into the subretinal space. To determine whether there a link between oxidative stress and extracellular matrix (ECM) degradation by retinal pigment epithelium, present study focused on effect MMP-1 MMP-3 expression, two enzymes substrate specificity for components membrane. Methods.: Cultured human RPE cells were exposed to...
Fifteen variants in 10q26 are strong linkage disequilibrium and associated with an increased risk for age-related macular degeneration (AMD), a frequent cause of blindness developed countries. These tag single-risk haplotype encompassing the genes ARMS2 (age-related maculopathy susceptibility 2) part HTRA1 (HtrA serine peptidase 1). To define true AMD gene 10q26, several studies have focused on influence alleles expression and/or HTRA1, but results been inconsistent. By heterologous genomic...
Abstract Purpose To compare the efficacy and safety of ranibizumab 0.5 mg versus dexamethasone 0.7 according to their European labels in macular oedema secondary branch retinal vein occlusion (BRVO) a 6‐month, phase IIIb, randomized trial. Methods Patients received either monthly for 3 months followed by Pro re nata (PRN) treatment ( n = 126) or sustained‐release implant PRN sham injections 118). Main outcomes were mean average change best‐corrected visual acuity (BCVA) from baseline month 1...
The influence of stem cells and lentiviral expression basic fibroblastic growth factor (bFGF) on tendon healing remodelling was investigated in an in-vivo long-term (12 weeks) rat Achilles defect model. In sixty male Lewis rats, complete defects (2.4 mm) were created either left untreated (PBS) or treated by injection lentivirally expressing the enhanced green fluorescence marker gene eGFP (MSC-LV-eGFP) fibroblast bFGF (MSC-LV-bFGF). Tendons harvested after 12 weeks underwent biomechanical...